Cargando…

Limited therapeutic potential of astrocyte elevated gene-1 transduction in an animal model of Parkinson's disease

Detalles Bibliográficos
Autores principales:	Leem, Eunju, Kim, Sang Ryong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513990/ https://www.ncbi.nlm.nih.gov/pubmed/32246631 http://dx.doi.org/10.4103/1673-5374.280315

Ejemplares similares

Inhibition of microglial activation and induction of neurotrophic factors by flavonoids: a potential therapeutic strategy against Parkinson's disease
por: Kim, Sang Ryong
Publicado: (2015)

Control of Reactive Oxygen Species for the Prevention of Parkinson’s Disease: The Possible Application of Flavonoids
por: Kim, Tae Yeon, et al.
Publicado: (2020)

Perspective: Therapeutic Potential of Flavonoids as Alternative Medicines in Epilepsy
por: Kwon, Jae Young, et al.
Publicado: (2019)

hiPSC-based models to decipher the contribution of human astrocytes to Alzheimer’s disease and potential therapeutics
por: TCW, Julia, et al.
Publicado: (2023)

Upregulation of neuronal astrocyte elevated gene-1 protects nigral dopaminergic neurons in vivo
por: Leem, Eunju, et al.
Publicado: (2018)

Therapeutic Potential of AAV1-Rheb(S16H) Transduction against Neurodegenerative Diseases
por: Nam, Youngpyo, et al.
Publicado: (2021)

Gut microbiota: a potential therapeutic target for Parkinson’s disease
por: Baizabal-Carvallo, José Fidel
Publicado: (2020)

Astrocyte dysfunction following molybdenum-associated purine loading could initiate Parkinson’s disease with dementia
por: Bourke, Christopher A.
Publicado: (2018)

Probing mammalian touch transduction
por: Bautista, Diana M., et al.
Publicado: (2011)

Naringin: A Protector of the Nigrostriatal Dopaminergic Projection
por: Jung, Un Ju, et al.
Publicado: (2014)

Therapeutic Potential of AAV1-Rheb(S16H) Transduction Against Alzheimer’s Disease
por: Moon, Gyeong Joon, et al.
Publicado: (2019)

Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson’s disease
por: Hare, Dominic J, et al.
Publicado: (2017)

Prothrombin Kringle-2: A Potential Inflammatory Pathogen in the Parkinsonian Dopaminergic System
por: Leem, Eunju, et al.
Publicado: (2016)

TRPA1 and Cold Transduction: An Unresolved Issue?
por: Caspani, Ombretta, et al.
Publicado: (2009)

Craniofacial Ciliopathies and the Interpretation of Hedgehog Signal Transduction
por: Liu, Karen J.
Publicado: (2016)

Designing nanocarriers to overcome the limitations in conventional drug administration for Parkinson’s disease
por: García-Muñoz, Rafael A., et al.
Publicado: (2022)

Astrocytic aquaporin 4 subcellular translocation as a therapeutic target for cytotoxic edema in ischemic stroke
por: Patabendige, Adjanie, et al.
Publicado: (2022)

Mammalian target of rapamycin complex 1 as an inducer of neurotrophic factors in dopaminergic neurons
por: Kim, Sang Ryong
Publicado: (2014)

Beneficial effects of AAV1-Rheb(S16H) administration in the adult hippocampus
por: Kim, Sang Ryong
Publicado: (2020)

Application of flavonoids for the protection of nigral dopaminergic neurons from oxidative stress
por: Kim, Sang Ryong
Publicado: (2020)

The Interfaces Between Signal Transduction Pathways: IGF-1/mTor, p53 and the Parkinson Disease Pathway
por: Levine, Arnold J., et al.
Publicado: (2012)

Astrocytic Kir4.1 potassium channels as a novel therapeutic target for epilepsy and mood disorders
por: Ohno, Yukihiro
Publicado: (2018)

Functional imaging of astrocyte activity
por: Kato, Hiroki, et al.
Publicado: (2020)

Astrocyte evolution and human specificity
por: Falcone, Carmen, et al.
Publicado: (2022)

Non-Clinical Models for Neurodegenerative Diseases: Therapeutic Approach and Drug Validation in Animal Models
por: Fernandez, Caridad Ivette, et al.
Publicado: (2017)

Genetics provides new individualized therapeutic targets for Parkinson’s disease
por: Garcia, Eric Joshua, et al.
Publicado: (2020)

Oxidative stress: culprit or consequence in Alzheimer’s amyloidopathy
por: Sharma, Chanchal, et al.
Publicado: (2023)

Limitations of Animal Models of Parkinson's Disease
por: Potashkin, J. A., et al.
Publicado: (2010)

Potential role of biofeedback therapy for Parkinson’s disease
por: Kotani, Naoya, et al.
Publicado: (2021)

Combined approaches using adverse outcome pathways and big data to find potential diseases associated with humidifier disinfectant
por: Leem, Jong Han, et al.
Publicado: (2016)

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

Prothrombin kringle-2, a mediator of microglial activation: new insight in Alzheimer’s disease pathogenesis
por: Lee, Jae Man, et al.
Publicado: (2022)

Bacterial melanin in rat models of Parkinson's disease: a potential neuroprotective strategy
por: Petrosyan, Tigran
Publicado: (2015)

Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson’s disease
por: Yang, Yunseon, et al.
Publicado: (2022)

Multicellularity in animals: The potential for within-organism conflict
por: Howe, Jack, et al.
Publicado: (2022)

Current opinion on a role of the astrocytes in neuroprotection
por: Teo, Leon, et al.
Publicado: (2018)

Biomonitors of atmospheric nitrogen deposition: potential uses and limitations
por: Díaz-Álvarez, Edison A, et al.
Publicado: (2018)

Effects of Electrical Stimulation of the Cell: Wound Healing, Cell Proliferation, Apoptosis, and Signal Transduction
por: Katoh, Kazuo
Publicado: (2023)

Interleukin 4-induced neuroprotection and regulation of microglia activation as a therapeutic approach in the MPTP model of Parkinson's disease
por: Spittau, Björn
Publicado: (2017)

Emerging non-invasive therapeutic approaches targeting hypocholinergic neural systems in Parkinson’s disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9isuhuvnja9hae7ko103ddnoop